STAT+: Money troubles and M&A: What’s on biotech insiders’ minds ahead of a not-so-celebratory JPM week
Nearly 70% of biotech insiders say financing — such as raising venture capital or launching an IPO — will be a challenge in 2023.
News
STAT+: New Biogen CEO: New drug launches, more cost cuts, but no ‘radical left turns’ needed
SAN FRANCISCO — In some of his first extended comments since taking over as Biogen’s CEO, Chris Viehbacher described the commercial launches this year of an Alzheimer’s treatment and a… […]
News
STAT+: A flurry of pharma acquisitions kick off JPM week after a slow year for deals
Four life science companies have announced acquisitions worth roughly $4.5 billion in total, raising hopes that 2023 will yield more M&A. […]
News
STAT+: Regeneron’s George Yancopoulos admits some regret, but ‘I don’t apologize’
In some of his first public remarks since getting booed on stage last month over Alzheimer’s drug remarks, Regeneron’s George Yancopoulos acknowledged in an interview he could’ve handled things differently. […]
